Potential therapeutic targets for targeted treatment are the surface receptors of cancer cells such as 1) the endothelial receptor (epidermal growth factor receptor, EGFR) or C-KIT); 2) parts of the protein kinase of the MAP kinase signaling pathway (Ras/MAPK) or the B protein kinase (PI3K/Akt); 3) induction of damage to single or double helix DNA damage by specific chemotherapeutic agents; and 4) inhibition of repair of the defective DNA (inhibitors PARP-poly-ADP-ribose polymerase inhibitors) [12]. This evidence concerns the gene AKT1 and cancer.